Got Questions? Send us a message!

We trace fenbendazole’s unlikely path from dewormer to a serious subject in oncology, clarifying how microtubules and p53 shape the scientific interest and where the evidence genuinely stands. We share practical guardrails on sourcing, clinical partnership, and mindset while separating early promise from proof.

• selective toxicity explains parasite targeting while sparing mammals
• microtubule disruption leads to mitotic arrest and apoptosis
• p53 stabilization as a potential secondary anticancer effect
• limits of preclinical data and the gap to human trials
• bioavailability, solubility and metabolism as key hurdles
• sourcing quality and COAs as non‑negotiables
• working with clinicians to monitor safety and interactions
• adopting curiosity over certainty as new data emerges

FenbendazoleHelp.org and its informational resources are not intended to provide personal medical advice. Always consult your physician before beginning any protocols. No information on this site is intended to diagnose, treat, or otherwise replace the opinion of medical professionals. The purpose of this site is for informational purposes ONLY.